On January 17, Hybio Pharmaceutical Co.Ltd(300199) issued a change announcement. The cumulative deviation of the closing price increase of the company's shares for three consecutive trading days on January 13, January 14 and January 17 exceeded 30%, which belongs to the abnormal fluctuation of stock trading.
The company suggests that the covid-19 virus polypeptide nasal spray developed in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences needs to carry out many links such as live toxicity experiment, preclinical research, clinical research, pharmaceutical research and market promotion of covid-19 virus and its variants in the follow-up, and there is a risk that the clinical progress and effectiveness do not meet the expectations.
The company pointed out that there are covid-19 preventive and therapeutic drugs in different R & D stages in the world. A number of covid-19 vaccines have been listed in China, and a number of antibodies and small molecule drugs are also in different R & D stages. The covid-19 virus polypeptide nasal spray has uncertainty in the market competition pattern after listing. In addition, affected by many factors such as overseas epidemic development and control, drug use selection and overseas market promotion, there is still uncertainty about whether the clinical trial application and products can be successfully approved for listing.
